CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 - PubMed (original) (raw)

Practice Guideline

CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022

Deborah Dowell et al. MMWR Recomm Rep. 2022.

Abstract

This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative or end-of-life care. The guideline addresses the following four areas: 1) determining whether or not to initiate opioids for pain, 2) selecting opioids and determining opioid dosages, 3) deciding duration of initial opioid prescription and conducting follow-up, and 4) assessing risk and addressing potential harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Recommendations are based on systematic reviews of the scientific evidence and reflect considerations of benefits and harms, patient and clinician values and preferences, and resource allocation. CDC obtained input from the Board of Scientific Counselors of the National Center for Injury Prevention and Control (a federally chartered advisory committee), the public, and peer reviewers. CDC recommends that persons with pain receive appropriate pain treatment, with careful consideration of the benefits and risks of all treatment options in the context of the patient's circumstances. Recommendations should not be applied as inflexible standards of care across patient populations. This clinical practice guideline is intended to improve communication between clinicians and patients about the benefits and risks of pain treatments, including opioid therapy; improve the effectiveness and safety of pain treatment; mitigate pain; improve function and quality of life for patients with pain; and reduce risks associated with opioid pain therapy, including opioid use disorder, overdose, and death.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest; no significant conflicts of interest were disclosed.

Similar articles

Cited by

References

    1. Chou R, Hartung D, Turner J, et al. Opioid treatments for chronic pain. Comparative effectiveness review no. 229. Rockville, MD: Agency for Healthcare Research and Quality; 2020. - PubMed
    1. Skelly A, Chou R, Dettori J, et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review update. Comparative effectiveness review no. 227. Rockville, MD: Agency for Healthcare Research and Quality; 2020. - PubMed
    1. McDonagh M, Selph S, Buckley D, et al. Nonopioid pharmacologic treatments for chronic pain. Comparative effectiveness review no. 228. Rockville, MD: Agency for Healthcare Research and Quality; 2020. - PubMed
    1. Chou R, Wagner J, Ahmed A, et al. Treatments for acute pain: a systematic review. Comparative effectiveness review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020. - PubMed
    1. Halker Singh R, VanderPluym J, Morrow A, et al. Acute treatments for episodic migraine. Comparative effectiveness review no. 239. Rockville, MD: Agency for Healthcare Research and Quality; 2020. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources